当前位置：
X-MOL 学术
›
J. Mater. Chem. B
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A self-immolative and DT-diaphorase-activatable prodrug for drug-release tracking and therapy.
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2017-03-20 , DOI: 10.1039/c7tb00266a Bowen Li 1 , Peilian Liu , Donghang Yan , Fang Zeng , Shuizhu Wu
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2017-03-20 , DOI: 10.1039/c7tb00266a Bowen Li 1 , Peilian Liu , Donghang Yan , Fang Zeng , Shuizhu Wu
Affiliation
|
DT-diaphorase, which catalyzes the reduction of various biological substances like quinones, is overexpressed in some malignant tumors. However, exploiting this attractive property for the controlled release of an active drug from a prodrug is yet to be fully taken advantage of. Herein we report a DT-diaphorase-based prodrug for concomitant drug-release imaging and cancer chemotherapy. This prodrug system is composed of two camptothecin (CPT) moieties as the active anticancer drug, a DT-diaphorase-responsive quinone propionic acid moiety and a set of self-immolative linkers. The presence of DT-diaphorase leads to the release of two CPT molecules and restores the fluorescence of the latter, thereby realizing the fluorescence monitoring of the DT-diaphorase level as well as the tracking of CPT release. Upon internalization by DT-diaphorase overexpressing cells, the prodrug can release fluorescent CPT and exhibit high cytotoxicity (half-maximal inhibitory concentration 0.71 μM) towards the cancer cells. This prodrug features on-demand enzyme-biomarker-triggered drug release as well as self-monitoring of drug release, therapeutic effect and biomarker level. This new strategy may provide an effective approach for constructing prodrugs with enhanced drug loading as well as controllability for drug release and tracking.
中文翻译：
一种自消灭性和DT-黄递酶可激活的前药，用于药物释放跟踪和治疗。
DT-心肌黄递酶催化某些生物物质（例如醌）的还原，在某些恶性肿瘤中过表达。然而，利用这种吸引人的特性来控制活性药物从前药中的释放尚未得到充分利用。本文中，我们报告了基于DT-黄递酶的前药，用于伴随的药物释放成像和癌症化疗。该前药系统由作为活性抗癌药的两个喜树碱（CPT）部分，一个DT-心肌黄递酶反应性醌丙酸部分和一组自消灭性连接体组成。DT-黄递酶的存在导致两个CPT分子的释放并恢复后者的荧光，从而实现了DT-黄递酶水平的荧光监测以及CPT释放的跟踪。在被DT-diaphorase过表达的细胞内化后，前药可以释放荧光CPT并显示出对癌细胞的高细胞毒性（半数最大抑制浓度为0.71μM）。该前药具有按需酶-生物标志物触发的药物释放以及对药物释放，治疗效果和生物标志物水平的自我监控的功能。这一新策略可能为构建具有增加的药物载量以及药物释放和追踪的可控性的前药提供有效的方法。
更新日期：2017-03-10
中文翻译：
一种自消灭性和DT-黄递酶可激活的前药，用于药物释放跟踪和治疗。
DT-心肌黄递酶催化某些生物物质（例如醌）的还原，在某些恶性肿瘤中过表达。然而，利用这种吸引人的特性来控制活性药物从前药中的释放尚未得到充分利用。本文中，我们报告了基于DT-黄递酶的前药，用于伴随的药物释放成像和癌症化疗。该前药系统由作为活性抗癌药的两个喜树碱（CPT）部分，一个DT-心肌黄递酶反应性醌丙酸部分和一组自消灭性连接体组成。DT-黄递酶的存在导致两个CPT分子的释放并恢复后者的荧光，从而实现了DT-黄递酶水平的荧光监测以及CPT释放的跟踪。在被DT-diaphorase过表达的细胞内化后，前药可以释放荧光CPT并显示出对癌细胞的高细胞毒性（半数最大抑制浓度为0.71μM）。该前药具有按需酶-生物标志物触发的药物释放以及对药物释放，治疗效果和生物标志物水平的自我监控的功能。这一新策略可能为构建具有增加的药物载量以及药物释放和追踪的可控性的前药提供有效的方法。
京公网安备 11010802027423号